Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRedx Pharma Regulatory News (REDX)

Share Price Information for Redx Pharma (REDX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11.40
Bid: 10.50
Ask: 12.00
Change: 0.00 (0.00%)
Spread: 1.50 (14.286%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 11.40
REDX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8 (OPD) Redx Pharma plc

17 Mar 2020 14:30

RNS Number : 4869G
Redx Pharma plc
17 March 2020
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Redx Pharma plc ("Redx")

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Redx Pharma plc

(d) Is the discloser the offeror or the offeree?

OFFEROR / OFFEREE

(e) Date position held:

The latest practicable date prior to the disclosure

17 March 2020

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

YES / NO / N/A

If YES, specify which:

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

1p ordinary shares

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

n/a

n/a

(2) Cash-settled derivatives:

 

n/a

n/a

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

n/a

n/a

 

TOTAL:

n/a

n/a

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

n/a

Details, including nature of the rights concerned and relevant percentages:

n/a

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

Interest of Redx Directors and connected advisers in Redx shares:

Name

Number of Shares

% of issued share capital

Iain Ross

600,000

0.32

Dr. Bernhard Kirschbaum

50,000

0.02

Peter Presland

120,000

0.06

WG Partners LLP

114,593

0.06

 

Interest of Redx Directors in options over Redx shares:

Name

No. of options

Exercise price

Vesting date

Expiry date

Lisa Anson

600,000

13.75p

4 June 2018

3 June 2028

Lisa Anson

600,000

20p

4 June 2018

3 June 2028

Lisa Anson

600,000

27p

4 June 2019

3 June 2028

Lisa Anson

600,000

35p

4 June 2019

3 June 2028

Lisa Anson

600,000

42.5p

4 June 2020

3 June 2028

Lisa Anson

600,000

50p

4 June 2020

3 June 2028

Dr. James Mead

200,000

13.75p

13 February 2019

12 February 2029

Dr. James Mead

200,000

20p

13 February 2019

12 February 2029

Dr. James Mead

200,000

27p

13 February 2020

12 February 2029

Dr. James Mead

200,000

35p

13 February 2020

12 February 2029

Dr. James Mead

200,000

42.5p

13 February 2021

12 February 2029

Dr. James Mead

200,000

50p

13 February 2021

12 February 2029

 

 

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

YES/NO

Supplemental Form 8 (SBL)

YES/NO

 

 

Date of disclosure:

17 March 2020

Contact name:

James Mead

Telephone number:

01625 496 609

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FEEFLFLSVSIDLII
Date   Source Headline
24th May 20174:35 pmRNSSuspension - Redx Pharma plc
17th May 20177:00 amRNSInterim results for six months ended 31 March 2017
15th May 20177:00 amRNSPreclinical efficacy data presented on RXC005
4th May 20177:00 amRNSNotice of Interim Results
20th Apr 201711:20 amRNSResult of AGM
20th Apr 20177:00 amRNSAppointment of Chairman
7th Apr 20173:56 pmRNSNotice of Annual General Meeting
3rd Apr 20177:15 amRNSHardman: CARB-X - new strategic collaboration
30th Mar 20174:03 pmRNSRedx Pharma awarded US$1 million grant by CARB-X
21st Mar 20179:05 amRNSFinal Results Year Ended 30 September 2016
7th Mar 20174:33 pmRNSHolding(s) in Company
3rd Mar 20172:35 pmRNSHolding(s) in Company
3rd Mar 20172:27 pmRNSHolding(s) in Company
3rd Mar 20172:17 pmRNSHolding(s) in Company
2nd Mar 20175:01 pmRNSHolding(s) in Company
2nd Mar 20177:50 amRNSRedx presentations at AACR 2017
28th Feb 201710:35 amRNSResult of General Meeting and Issue of Equity
27th Feb 20175:50 pmRNSResult of Open Offer
10th Feb 20171:00 pmRNSResult of Placing
9th Feb 20177:00 amRNSAccelerated Book Build
8th Feb 20176:30 pmRNSAccelerated Book Build
27th Jan 20177:00 amRNSGrowing opportunity for Porcupine inhibitors
6th Dec 20167:00 amRNSReversible BTK poster at ASH meeting
30th Nov 20167:00 amRNSRXC004 pre-clinical profile
16th Nov 20163:22 pmRNSHolding(s) in Company
4th Nov 20167:00 amRNSReversible BTK data at ASH meeting
20th Oct 20167:00 amRNSDevelopment candidate chosen for leukaemia program
11th Oct 20169:32 amRNSExercise of Options and Total Voting Rights
27th Sep 20167:00 amRNSDiscovery of breakthrough antibiotic compounds
23rd Sep 20164:07 pmRNSHolding(s) in Company
21st Sep 20168:50 amRNSHolding(s) in Company
19th Sep 20167:00 amRNSRe: Porcupine inhibitor and cancer immunotherapy
16th Sep 201611:31 amRNSHolding(s) in Company
14th Sep 201610:47 amRNSHolding(s) in Company
8th Sep 20167:00 amRNSBoard & Senior Management Changes
6th Sep 20167:00 amRNSSupply agreement for expected clinical trial
8th Aug 201610:55 amRNSHardman Research: Moving to clinic, rising value
17th Jun 201612:15 pmRNSRedx to present at ASM Microbe 2016 Conference
24th May 20167:00 amRNSProof of concept with key oncology lead
24th May 20167:00 amRNSHalf-year Report
19th May 20167:00 amRNSRe Review on Antimicrobial Resistance
9th May 20167:00 amRNSBoard Appointment
26th Apr 20163:37 pmRNSHolding(s) in Company
19th Apr 20164:52 pmRNSHolding(s) in Company
18th Apr 20167:00 amRNSHolding(s) in Company
15th Apr 20165:10 pmRNSHolding(s) in Company
13th Apr 201612:06 pmRNSResult of General Meeting and Issue of Equity
4th Apr 20162:58 pmRNSGrant of Options
4th Apr 201612:59 pmRNSResult of General Meeting
4th Apr 20167:00 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.